Summary:
- The article discusses the clinical development and subsequent commercialization of RZL-012 (a drug for neurofibromatosis type 1), highlighting the intersection of breakthrough pharmaceutical innovation and high-cost pricing models.
- It examines the economic and ethical implications of "orphan drug" pricing strategies, focusing on the tension between the significant R&D investment required for precision medicine and the accessibility of these treatments for patients.